Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

Combined effect of recombinant human bone morphogenetic protein-2 and low level laser irradiation on bisphosphonate-treated osteoblasts

  • Jeong, Seok-Young (Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University) ;
  • Hong, Ji-Un (Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University) ;
  • Song, Jae Min (Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University) ;
  • Kim, In Ryoung (Department of Oral Anatomy, School of Dentistry, Pusan National University) ;
  • Park, Bong Soo (Department of Oral Anatomy, School of Dentistry, Pusan National University) ;
  • Kim, Chul Hoon (Department of Oral and Maxillofacial Surgery, Dong-A University Hospital) ;
  • Shin, Sang Hun (Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University)
  • Received : 2018.03.14
  • Accepted : 2018.06.08
  • Published : 2018.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: The purpose of this study was to evaluate the synergic effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) and low-level laser therapy (LLLT) on bisphosphonate-treated osteoblasts. Materials and Methods: Human fetal osteoblast cells (hFOB 1.19) were cultured with $100{\mu}M$ alendronate. Low-level Ga-Al-As laser alone or with 100 ng/mL rhBMP-2 was then applied. Cell viability was measured with MTT assay. The expression levels of receptor activator of nuclear factor kappa-B ligand (RANKL), macrophage colony-stimulating factor (M-CSF), and osteoprotegerin (OPG) were analyzed for osteoblastic activity inducing osteoclastic activity. Collagen type and transforming growth factor beta-1 were also evaluated for bone matrix formation. Results: The results showed that rhBMP-2 and LLLT had a synergic effect on alendronate-treated osteoblasts for enhancing osteoblastic activity and bone matrix formation. Between rhBMP-2 and LLLT, rhBMP-2 exhibited a greater effect, but did not show a significant difference. Conclusion: rhBMP-2 and LLLT have synergic effects on bisphosphonate-treated osteoblasts through enhancement of osteoblastic activity and bone formation activity.

Keywords

References

  1. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008;44:857-69. https://doi.org/10.1016/j.oraloncology.2007.11.012
  2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. https://doi.org/10.1016/S0278-2391(03)00720-1
  3. Lee JK, Kim KW, Choi JY, Moon SY, Kim SG, Kim CH, et al. Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report. J Korean Assoc Oral Maxillofac Surg 2013;39:9-13. https://doi.org/10.5125/jkaoms.2013.39.1.9
  4. Woo SB, Hellstein JW, Kalmar JP. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61. https://doi.org/10.7326/0003-4819-144-10-200605160-00009
  5. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23. https://doi.org/10.1016/j.joms.2006.10.061
  6. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996;97:2692-6. https://doi.org/10.1172/JCI118722
  7. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993;91:2004-11. https://doi.org/10.1172/JCI116422
  8. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995;17:137-44. https://doi.org/10.1016/S8756-3282(95)00150-6
  9. Aubin JE, Triffitt JT. Mesenchymal stem cells and the osteoblast lineage. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. 2nd ed. New York: Academic; 2002.
  10. Tay JY, Bay BH, Yeo JF, Harris M, Meghji S, Dheen ST. Identification of RANKL in osteolytic lesions of the facial skeleton. J Dent Res 2004;83:349-53. https://doi.org/10.1177/154405910408300415
  11. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76. https://doi.org/10.1016/S0092-8674(00)81569-X
  12. Khadra M, Lyngstadaas SP, Haanaes HR, Mustafa K. Effect of laser therapy on attachment, proliferation and differentiation of human osteoblast-like cells cultured on titanium implant material. Biomaterials 2005;26:3503-9. https://doi.org/10.1016/j.biomaterials.2004.09.033
  13. Urist MR. Bone: formation by autoinduction. Science 1965;150:893-9. https://doi.org/10.1126/science.150.3698.893
  14. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors 2004;22:233-41. https://doi.org/10.1080/08977190412331279890
  15. Kwon TK, Song JM, Kim IR, Park BS, Kim CH, Cheong IK, et al. Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts. J Korean Assoc Oral Maxillofac Surg 2014;40:291-6. https://doi.org/10.5125/jkaoms.2014.40.6.291
  16. Marx RE. Clinical concerns of alendronate use. J Oral Maxillofac Surg 2008;66:1322. https://doi.org/10.1016/j.joms.2008.02.004
  17. Rustemeyer J, Bremerich A. Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature. Clin Oral Investig 2009;14:59-64.
  18. Garcia-Moreno C, Serrano S, Nacher M, Farre M, Diez A, Marinoso ML, et al. Effect of alendronate on cultured normal human osteoblasts. Bone 1998;22:233-9. https://doi.org/10.1016/S8756-3282(97)00270-6
  19. Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996;137:2324-33. https://doi.org/10.1210/endo.137.6.8641182
  20. Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996;18:9-14. https://doi.org/10.1016/8756-3282(95)00426-2
  21. Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, et al. OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2-year genistein administration. J bone Miner Res 2008;23:715-20. https://doi.org/10.1359/jbmr.080201
  22. Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB, et al. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology (Oxford) 2008;47:1775-9. https://doi.org/10.1093/rheumatology/ken385
  23. Ashizawa N, Graf K, Do YS, Nunohiro T, Giachelli CM, Meehan WP, et al. Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. J Clin Invest 1996;98:2218-27. https://doi.org/10.1172/JCI119031
  24. Murry CE, Giachelli CM, Schwartz SM, Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol 1994;145:1450-62.
  25. Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, Hirokawa K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 1993;92:2814-20. https://doi.org/10.1172/JCI116901
  26. Reinholt FP, Hultenby K, Oldberg A, Heinegard D. Osteopontin: a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A 1990;87:4473-5. https://doi.org/10.1073/pnas.87.12.4473
  27. Itoh K, Udagawa N, Katagiri T, Iemura S, Ueno N, Yasuda H, et al. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factorkappaB ligand. Endocrinology 2001;142:3656-62. https://doi.org/10.1210/endo.142.8.8300
  28. Zheng Y, Wang L, Zhang X, Zhang X, Gu Z, Wu G. BMP2/7 heterodimer can modulate all cellular events of the in vitro RANKLmediated osteoclastogenesis, respectively, in different dose patterns. Tissue Eng Part A 2012;18:621-30. https://doi.org/10.1089/ten.tea.2011.0366
  29. Goldman L, Goldman B, Van Lieu N. Current laser dentistry. Lasers Surg Med 1987;6:559-62. https://doi.org/10.1002/lsm.1900060616
  30. Stein A, Benayahu D, Maltz L, Oron U. Low-level laser irradiation promotes proliferation and differentiation of human osteoblasts in vitro. Photomed Laser Surg 2005;23:161-6. https://doi.org/10.1089/pho.2005.23.161
  31. Renno AC, McDonnell PA, Parizotto NA, Laakso EL. The effects of laser irradiation on osteoblast and osteosarcoma cell proliferation and differentiation in vitro. Photomed Laser Surg 2007;25:275-80. https://doi.org/10.1089/pho.2007.2055
  32. Kiyosaki T, Mitsui N, Suzuki N, Shimizu N. Low-level laser therapy stimulates mineralization via increased Runx2 expression and ERK phosphorylation in osteoblasts. Photomed Laser Surg 2010;28 Suppl 1:S167-72. https://doi.org/10.1089/pho.2009.2693
  33. Shin SH, Kim KH, Choi NR, Kim IR, Park BS, Kim YD, et al. Effect of low-level laser therapy on bisphosphonate-treated osteoblasts. Maxillofac Plast Reconstr Surg 2016;38:48. https://doi.org/10.1186/s40902-016-0095-8
  34. Hirata S, Kitamura C, Fukushima H, Nakamichi I, Abiko Y, Terashita M, et al. Low-level laser irradiation enhances BMP-induced osteoblast differentiation by stimulating the BMP/Smad signaling pathway. J Cell Biochem 2010;111:1445-52. https://doi.org/10.1002/jcb.22872

Cited by

  1. Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors vol.8, pp.1, 2018, https://doi.org/10.1038/s41413-020-0088-1
  2. In Vitro Cytological Responses against Laser Photobiomodulation for Periodontal Regeneration vol.21, pp.23, 2018, https://doi.org/10.3390/ijms21239002
  3. Laser and LED photobiomodulation effects in osteogenic or regular medium on rat calvaria osteoblasts obtained by newly forming bone technique vol.36, pp.3, 2021, https://doi.org/10.1007/s10103-020-03056-5
  4. Serial administration of rhBMP‐2 and alendronate enhances the differentiation of osteoblasts vol.24, pp.10, 2018, https://doi.org/10.1111/1756-185x.14189